Adicet Bio (ACET) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET:
- Adicet Bio’s Promising Off-the-Shelf Cell Therapy Garners Buy Rating Due to Positive Clinical Outcomes and Strong Market Position
- Adicet Bio price target raised to $8 from $7 at Guggenheim
- Adicet Bio Receives Nasdaq Extension for Compliance
- Adicet Bio announces $80M registered direct offering
- Adicet Bio Announces Major Stock Offering Agreement